Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition containing NMN for improving intelligence and invigorating brain

A composition and drug technology, applied in the field of medicine, can solve problems such as slowness

Inactive Publication Date: 2020-10-13
深圳市旷逸生物科技有限公司
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, it has not been confirmed that NMN can inhibit the inevitable OS damage during the natural aging process of the body; more importantly, the OS damage process accompanying aging is slow and continuous, and does not produce acute hemorrhage. , large-scale damage, so there must be a world of difference in the concentration, method and pharmacology of the drug

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition containing NMN for improving intelligence and invigorating brain
  • Pharmaceutical composition containing NMN for improving intelligence and invigorating brain
  • Pharmaceutical composition containing NMN for improving intelligence and invigorating brain

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0038] The preparation of embodiment 1 alpine edelweiss extract

[0039] Accurately weigh 1000g of alpine edelweiss fresh grass, crush and preform into powder, add 2000mL of 95% ethanol at a material-to-liquid ratio of 1:2 (m / v), stir and mix, and ultrasonically treat for 15min (ultrasonic power: 300w, ultrasonic temperature: 25°C). Add 8 L of pure water 8 times the cell mass to the edelweiss solution treated by ultrasonic wall breaking, extract at a high temperature of 100°C for 1 hour, and then centrifuge at 6000g for 10 minutes, and the obtained supernatant is liquid A.

[0040] Accurately weigh 1000g of alpine edelweiss hay powder, add 10000mL of 95% ethanol in batches at a material-to-liquid ratio of 1:10 (m / v) for Soxhlet extraction until colorless, and centrifuge at 6000g for 10 minutes to collect the extract as liquid B.

[0041] Take 3L of liquid A and 3L of liquid B, mix them evenly, concentrate under reduced pressure and freeze-dry to obtain the extract C of edelwe...

Embodiment 2

[0043] The preparation of embodiment 2 pharmaceutical compositions

[0044] After weighing 0.1g of NMN and 60g of extract A and mixing them uniformly, the pharmaceutical composition A is obtained;

[0045] Weigh 0.1g of NMN and 60g of extract B and mix them uniformly in equal proportions to obtain the pharmaceutical composition B;

[0046] Weigh 0.1g of NMN and 60g of extract C and mix them uniformly in equal proportions to obtain pharmaceutical composition C.

Embodiment 3

[0047] Example 3 Pharmaceutical composition intervention experiment on cognitive function of ApoE gene knockout mice

[0048] Experimental Materials:

[0049]1) Experimental animals: 72 8-week-old ApoE knockout male mice, 8 8-week-old C57BL / 6J male mice with the same genetic background, all purchased from Beijing Weitong Lihua Experimental Animal Technology Co., Ltd., in our company Animal rooms of clean grade are kept in groups.

[0050] 2) Test drugs:

[0051] The pharmaceutical composition prepared in Example 2 of the present invention;

[0052] NMN: Bangtai Bioengineering (Shenzhen) Co., Ltd.

[0053] 3) Main experimental instruments

[0054] The dark avoidance shuttle tester and Morris water maze system (including camera and analysis system) were purchased from Shanghai Ruanlong Technology Development Co., Ltd.

[0055] experimental method:

[0056] 1) Grouping:

[0057] The 72 ApoE gene knockout mice were randomly divided into 9 groups, namely drug A group, drug B...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a pharmaceutical composition for intervention of mild cognitive impairment. The pharmaceutical composition is composed of NMN, a leontopodium alpinum extract and a pharmaceutically acceptable auxiliary material. The leontopodium alpinum extract can significantly reduce the drug concentration of the NMN in intervention of mild cognitive impairment.

Description

technical field [0001] The invention belongs to the technical field of medicines. Specifically, the invention provides a brain-invigorating drug composition containing NMN, which is used for inhibiting mild cognitive impairment caused by oxidative stress. Background technique [0002] Mild cognitive impairment (Mild congnitive impairment, MCI) refers to a transitional stage of cognitive impairment between normal aging and Alzheimer's disease (AD) at the same age and education level. Avoid oxidative stress (Oxidative Stress, OS) damage. Therefore, the body's antioxidant therapy has become the main clinical means to prevent and inhibit MCI. [0003] However, after it was found that the use of conventional antioxidants such as vitamin C, vitamin E and β-carotene had little effect on improving the damage caused by oxidative stress, it began to turn to natural antioxidants such as resveratrol, stilbene glycosides, etc. Although the extraction, function, and mechanism research o...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K36/28A61K31/706A61P25/28
CPCA61K31/706A61K36/28A61K2236/30A61P25/28A61K2300/00
Inventor 沈洁
Owner 深圳市旷逸生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com